Teriparatide

Product Introduction:

Product Name: Teriparatide

Product source: Biotechnology synthesis

Product specifications: ≥ 99%

CAS   NO：52232-67-4

Detection method: HPLC

Molecular formula: C172H278N52O47S2

Molecular weight: 3890.49792

Active ingredient: rhPTH (1-34)

Product Description: White Powder

Product packaging: 2mg; 5mg; 10mg

Product storage: Keep away from light, seal and dry, 2-8 ° C

Shelf life: 24 months

Products  Description  

Xi'an Tihealth Teriparatide Product Overview

Xi'an Tihealth Biotechnology Co., Ltd. provides Teriparatide (Teriparatide) produced via biotechnological synthesis with a purity ≥99%, complying with USP/ChP pharmacopoeia standards. This key raw material for osteoporosis treatment is primarily supplied in 20 µg/0.2 mL pre-filled injection vials, formulated with stabilizers such as mannitol to ensure a clear, impurity-free solution with a pH of 4.5–5.5. Rigorous quality control includes HPLC, MS, and microbial testing to guarantee structural integrity, potency, and pharmaceutical-grade compliance.

Products Function

Teriparatide is the only approved bone-forming agent, mainly used to treat osteoporosis patients with high fracture risk. Its core function is to reduce the risk of vertebral and non-vertebral fractures by stimulating new bone formation, improving bone density and bone strength. It is especially suitable for patients who are ineffective or intolerant to traditional anti-resorptive drugs such as bisphosphonates.

Mechanism of action

1. Activation of osteoblasts: Intermittent injection of teriparatide can activate osteoblasts (bone-forming cells), promoting bone matrix synthesis and mineralization, and increasing bone density.

2. Inhibition of osteoclast activity: Short-term use can slightly inhibit osteoclast activity, reducing bone resorption, but the long-term effect still mainly promotes bone formation.

3. Regulation of calcium and phosphorus metabolism: By stimulating calcium reabsorption in the kidneys and calcium release from bone, it maintains blood calcium levels, but calcium and vitamin D supplementation should be combined to avoid hypocalcemia.

Products Application

 1. Indications:

• Postmenopausal osteoporosis in women (especially those with a history of fractures or those at extremely high risk of fractures).

• Male osteoporosis.

• Osteoporosis induced by glucocorticoids (osteoporosis caused by long-term use of hormones).

2. Special Requirements:

• For patients who have failed previous treatments or require rapid improvement in bone density (such as those with recent fractures).

• Some countries/regions have approved it for rare hereditary bone diseases such as X-linked hypophosphatemic rickets.

Pharmacological effects:

1. Bone formation promotion:

• After 12-18 months of treatment, vertebral bone density can increase by 6-12%, while non vertebral bone density can increase by 2-4%.

• Significantly reduce the risk of vertebral fractures (about 65%) and non vertebral fractures (about 20%).

2. Synergy with other drugs:

• After discontinuation, it is recommended to switch to anti bone resorption drugs (such as bisphosphonates and denosumab) to maintain bone density.

• Combined use with calcium and vitamin D can enhance therapeutic efficacy and reduce the risk of hypocalcemia.

Toxicological effects：

1. Potential risks:

Osteosarcoma risk: Long term use (>24 months) in animal experiments is associated with osteosarcoma, but human data is limited, and the FDA recommends use for no more than 24 months.

Hypocalcemia: It is necessary to monitor blood calcium levels and supplement calcium and vitamin D if necessary.

2. Other side effects:

Common: headache, nausea, injection site reactions (redness, swelling, pain).

Rare: Hypercalcemia (requiring monitoring of blood calcium and renal function).

The teriparatide provided by Xi 'an Tihealth Biotechnology Co., Ltd. is characterized by high purity, high stability and compliance with international standards, and is an important raw material in the field of osteoporosis treatment. Through scientifically verified pharmacological mechanisms and strict quality control, it provides reliable guarantees for the development of patients and terminal preparations.